Elysium

What Elysium does

Elysium Health is a New York-based, privately held longevity company founded in 2015 by Eric Marcotulli (CEO), Dan Alminana (COO), and Leonard Guarente, Ph.D. (Chief Scientist), a pioneer of sirtuin biology at MIT who discovered the SIR2-NAD+ connection. The company develops and sells a portfolio of evidence-based dietary supplements and one diagnostic test targeting specific hallmarks of human aging — cellular NAD+ decline (Basis, Signal), brain atrophy (Matter, co-developed with the University of Oxford), immune senescence (Format), skin aging (Mosaic, Cofactor), eye longevity (Vision), senescent cell accumulation (Senolytic Complex), muscle preservation (Creatine+, developed with Stanford's Center on Longevity), and epigenetic biological age measurement (Index, co-developed with Yale and Illumina). Each formulation is backed by human clinical trials published in peer-reviewed journals including Nature, Nature Aging, and Hepatology, and the company's Scientific Advisory Board includes 25+ researchers and 8 Nobel laureates from MIT, Harvard, Oxford, Yale, Stanford, and Columbia.

The company's business model is direct-to-consumer e-commerce through its own website (elysiumhealth.com) with a subscription-first revenue structure, complemented by marketplace listings on iHerb and a Canadian storefront (ca.elysiumhealth.com). Pricing ranges from approximately $35-$75 per monthly product subscription, with 23-38% discounts on annual prepaid plans driving recurring revenue mechanics; the Index diagnostic is sold as a one-time $299 kit. In May 2026 Elysium launched The Elysium Longevity Institute (TELI), a physician-led membership program offering personalized supplement and prescription protocols plus peptides, expanding the model from supplement-only DTC into clinical longevity services. Distribution is concentrated in the U.S., with Canada as the only formalized international market and several products (Creatine+, Cofactor, Vision, Index, Senolytic Complex) restricted to U.S. shipping.

Elysium has raised approximately $71 million across disclosed funding rounds from 2016-2021, with investors including General Catalyst, Breyer Capital, GISEV Family Office, Morningside, Sound Ventures, Mayo Clinic Ventures, and Western Technology Investment. The company maintains an 11-50 employee footprint and operates across 16+ clinical trials with institutions including Mayo Clinic, Massachusetts General Hospital, University of Copenhagen, Aarhus University, and Haukeland University Hospital, signaling sustained investment in clinical validation as a core competitive differentiator.

Name

Elysium

Legal name

Elysium Health

Website

https://elysiumhealth.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Elysium Health is a New York-based longevity company that develops and sells clinically validated dietary supplements (Basis, Matter, Signal, Format, Mosaic, Vision, Creatine+, Senolytic Complex) and an epigenetic biological age test (Index) targeting hallmarks of human aging, sold direct-to-consumer via subscription, with a Scientific Advisory Board of 25+ scientists including 8 Nobel laureates.

Ownership category

akta.pro rank

Product category

Longevity Dietary Supplements

NAICS

Food (Health) Supplement Retailers (456191)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Healthy Aging & Cognitive Support Supplements (CRADAGAM)

akta.pro secondary industries

Herbal & Botanical Supplements (CRADAGAD), Medical Wellness & Longevity (Health Screening, Biohacking, Anti-aging Programs) (THAJAHAI), Weight Management & Metabolic Supplements (CRADAGAG)

Keywords

• Longevity dietary supplements
• NAD+ cellular health
• Biological age testing
• Senolytic supplements
• Anti-aging nutraceuticals

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Marketing or Sales, Technology or R&D, Personnel, Operations

Revenue model

1. Direct-to-Consumer Supplement Sales: Elysium generates revenue primarily through direct-to-consumer sales of its supplement products via its e-commerce website (elysiumhealth.com). Products are sold through subscription plans (monthly and annual prepaid) and single one-time purchases. Annual subscription plans offer significant discounts (23-38%) over monthly plans, incentivizing long-term commitment. The company also sells through marketplace partners (iHerb) and country-specific storefronts (Canada).
2. Biological Age Testing (Index): Index, a one-time purchase biological age test kit ($299), generates revenue from at-home saliva-based epigenetic testing. Customers receive biological age, cumulative rate of aging, and nine system age scores. The test enables enrollment in the Aging Research Center, creating a research platform while driving repeat engagement.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

Elysium Health sells evidence-based dietary supplements and an at-home biological age test kit (Index) directly to consumers via its own e-commerce website on a subscription-first model. Its portfolio targets multiple hallmarks of aging — NAD+ decline, cellular senescence, inflammaging, mitochondrial dysfunction, brain atrophy, collagen loss, and visual decline — with clinically validated, branded formulations such as Basis, Signal, Matter, Cofactor, Mosaic, Vision, Format, Senolytic Complex, and Creatine+.

Product overview

Elysium Health is a longevity-focused supplement company offering a portfolio of evidence-based supplements targeting various aspects of aging. The product lineup includes Basis (NAD+ cellular aging), Creatine+ (longevity-focused creatine), Matter (brain aging with Oxford partnership), Cofactor (collagen with NAD+), Signal (mitochondrial/metabolic aging), Format (immune aging with senolytics), Mosaic (skin aging), Vision (eye longevity), Senolytic Complex (senescent cell clearance), Index (epigenetic biological age testing), and Longevity Starter Pack (bundled supplements). The company emphasizes clinical validation, scientific rigor, and partnerships with leading institutions like Stanford, Oxford, and Yale. Products range from daily supplements addressing specific aging hallmarks to diagnostic tests measuring biological age.

Differentiator

Problem solved

Functional benefit

Products and services

• Basis NAD+ cellular aging supplement containing proprietary nicotinamide riboside chloride (NR) and pterostilbene (PT), clinically proven to increase NAD+ levels by 40% in humans. NSF Certified for Sport. Sold to individual consumers via monthly or annual subscription, or one-time purchase.
• Matter Tri-vitamin complex for brain aging developed in partnership with the University of Oxford. Contains a patented B-vitamin complex (B6, folic acid, B12), omega-3 free fatty acids, and bilberry anthocyanins. Clinically proven to slow brain atrophy associated with mild memory concerns.
• Cofactor Advanced 4-in-1 collagen system combining collagen peptides (20g), nicotinamide riboside (250mg), hyaluronic acid (120mg), and vitamin C (90mg) to support collagen production, skin elasticity, hair, nails, bones, and joints.
• Signal NMN mitochondria supplement containing nicotinamide mononucleotide (250mg) and the SIRT3 Activation Complex (150mg honokiol and viniferin) to support mitochondrial health, increase NAD+ levels by 40% in humans, and protect and generate new mitochondria.
• Format Immune health supplement combining vitamin C, selenium, zinc, the Inflammaging Complex (tamarind, turmeric, broccoli extracts), and an intermittent Senolytic Complex (quercetin, fisetin, Chinese ginseng, chestnut rose) to address immune aging and chronic inflammation.
• Mosaic Skin aging supplement featuring a clinically proven Phytonutrient Carotenoid Complex combined with hyaluronic acid. Increases moisture content, reduces fine lines and wrinkles, improves skin texture and radiance, and raises skin carotenoid levels by 31% over 16 weeks.
• Vision Eye longevity supplement leveraging xanthophyll carotenoids and Elysium's proprietary PIXEL Complex, based on the AREDS 2 formula plus meso-zeaxanthin and astaxanthin. Clinically proven to increase macular pigment density and support visual performance.
• Senolytic Complex Senolytic supplement containing quercetin, fisetin, Chinese ginseng extract, and chestnut rose extract, proven to clear senescent human cells in laboratory studies. Taken intermittently (2 days per month for the Healthy Aging protocol).
• Creatine+ Advanced 3-in-1 creatine system for longevity, strength, and cognition combining creatine monohydrate (5g), HMB (1.5g), and pomegranate polyphenols standardized to urolithin A precursors (300mg). Targets muscle preservation, recovery, mitochondrial health, and cognition.
• Index At-home biological age test using DNA methylation analysis via the APEX algorithm (developed with Yale's Morgan Levine) run on a custom Illumina chip. Measures biological age, cumulative rate of aging, and nine system ages from a saliva sample, with results delivered approximately six weeks after sample receipt.
• Longevity Starter Pack Limited-edition bundle (one-month supply each) of four key supplements: Basis (cellular aging), Signal (metabolic aging), Matter (cognitive aging), and Format (immune aging). Sold as a one-time purchase.
• The Elysium Longevity Institute (TELI) Comprehensive physician-led longevity program offering personalized supplement and prescription protocols, peptides, vitamin injections, prescription medications, and ongoing physician support across healthy aging, energy, and metabolic health. Initial enrollment up to 10,000 members.

Quantifiable outcome

• Basis clinically proven to increase NAD+ levels by an average of 40% within 30 days (Nature Partner Journals: Aging and Mechanisms of Disease)
• +6 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

13 partnerships are on record, tiered core and minor.

• University of OxfordcoreStrategic or Co-development PartnerElysium partnered with the University of Oxford to develop Matter, a brain health supplement featuring a tri-vitamin complex (B6, folic acid, B12) that is patented to slow brain atrophy associated with mild memory concerns. The partnership is based on the VITACOG clinical study. Elysium co-founder Leonard Guarente and Scientific Advisory Board member A. David Smith (Professor Emeritus of Pharmacology at Oxford) lead the collaboration.
• Yale UniversitycoreStrategic or Co-development PartnerElysium partnered with Morgan Levine, Ph.D., of Yale University to develop Index, the company's biological age test. Levine's team contributed the machine learning approach (APEX) that powers Index's epigenetic analysis, which was published in Nature Aging and demonstrated to be the most precise among published epigenetic age measures. The collaboration also includes Mark B. Gerstein (Genomics & Bioinformatics) on the Scientific Advisory Board.
• Stanford University School of MedicinecoreStrategic or Co-development PartnerElysium collaborated with Theodore Leng, M.D., Director of Clinical and Translational Research at the Byers Eye Institute at Stanford University School of Medicine, to develop Vision, an eye longevity supplement. Leng serves as a Scientific Advisory Board member. Additionally, Michael Fredericson, M.D., Co-Director of the Stanford Center on Longevity and Professor of PM&R Sports Medicine at Stanford, provided advisement on Creatine+.
• IlluminacoreTechnology or IntegrationElysium partnered with Illumina, a biotechnology leader, to develop a custom Elysium chip for DNA methylation profiling in the Index biological age test. This custom chip enables the high-precision epigenetic analysis that underpins Index's biological age and system age calculations.
• Haukeland University HospitalminorStrategic or Co-development PartnerElysium initiated clinical trials at Haukeland University Hospital in Norway for NAD+ replenishment therapy (NADAPT trial for atypical parkinsonian syndromes) and for the experimental therapeutic EH301 for ALS (NO-ALS trial), partially funded by Norwegian government grants.
• Mayo ClinicminorStrategic or Co-development PartnerMayo Clinic conducted Elysium's Age-Related Frailty clinical trial (NCT03818802, complete and pending publication) evaluating whether NR-E can augment bone, skeletal muscle, and metabolic functions in aging. Mayo Clinic also conducted the AKI Phase II trial for Basis.
• Massachusetts General HospitalminorStrategic or Co-development PartnerMassachusetts General Hospital conducted the AKI Phase I human clinical trial in partnership with Elysium, enabling FDA approval of an Investigational New Drug application for Basis and the AKI Phase II trial. Results published in BMC Nephrology.
• University of CopenhagenminorStrategic or Co-development PartnerThe University of Copenhagen initiated the Slow Age clinical trial evaluating effects of NR-E, aerobic exercise, or time-restricted feeding on markers of aging, and a COPD trial evaluating NR-E on clinical outcomes in elderly COPD patients (results published in Nature Aging).
• Aarhus University (Denmark)minorStrategic or Co-development PartnerAarhus University in Denmark conducted a study in partnership with Elysium on muscle injury and repair using NRPT (nicotinamide riboside and pterostilbene), demonstrating that the combination was well tolerated but did not improve recruitment of muscle stem cells after muscle injury in older adults (published in PubMed).
• University of OklahomaminorStrategic or Co-development PartnerUniversity of Oklahoma initiated a human clinical trial evaluating the efficacy of NR-E on supporting brain vascular health and memory in aging (estimated completion December 2027, NCT05483465).
• Odense University Hospital (Denmark)minorStrategic or Co-development PartnerOdense University Hospital initiated a clinical trial evaluating the effect of NR-E or senolytics on bone resorption and formation markers in osteoporosis (estimated completion December 2025, NCT06018467).
• University of South AlabamaminorStrategic or Co-development PartnerThe University of South Alabama conducted a pilot study evaluating the effects of Basis (NRPT) supplementation on menopausal syndromes in women over 35, funded by Elysium Health. Results published in Frontiers in (NCT04841499).
• Spanish Foundation for ALS Research (FUNDELA)minorStrategic or Co-development PartnerElysium collaborated with FUNDELA on the EH301 pilot study for ALS treatment, showing evidence that EH301 can be used in treatment of amyotrophic lateral sclerosis (published in PubMed).

Scale indicators4 records

Recent moves6 records

Expansion highlights3 records

Direct peers

• ChromaDex: Public life sciences company commercializing nicotinamide riboside (Niagen) — the same active ingredient as Elysium's Basis — through the Tru Niagen consumer brand. ChromaDex is the most direct competitor in the NAD+ precursor space and shares a science-led DTC playbook.
• Thorne HealthTech: Premium DTC supplement brand with strong clinical and scientific positioning, NSF Certified for Sport products, practitioner channel, and subscription model. Competes directly with Elysium in the science-forward premium supplement category targeting health-optimization consumers.
• AG1 (Athletic Greens): High-profile premium subscription supplement brand selling daily nutritional blends DTC with celebrity/athlete endorsements and content-led marketing. Competes for the same affluent health-conscious consumer wallet share via a similar subscription-first DTC model.
• Tally Health: DTC longevity brand built around the TallyAge epigenetic biological age test, paired with supplements and skincare. Closest direct competitor to Elysium's Index test, with overlapping customer segment of health-optimization adults seeking biological age diagnostics.
• InsideTracker: Personalized health and longevity platform offering biomarker blood testing, biological age estimation, and supplement recommendations. Overlaps with Elysium's Index on the diagnostics-and-personalization side of the longevity stack.
• NOVOS: Longevity-focused DTC supplement brand explicitly built on the hallmarks-of-aging framework, with science-backed formulations targeting NAD+, senolytics, and DNA damage. Closest peer in the longevity-positioned niche supplement market.

Emerging players

• TruDiagnostic: Epigenetic age testing company offering biological age tests using DNA methylation algorithms, with a B2B focus on clinicians and researchers. Comparable technology stack to Elysium's Index, though distribution and target customer differ.

Broad incumbents

• Calico Life Sciences: Alphabet-backed longevity research organization explicitly named alongside Elysium as a leading player in the longevity market. Focuses on deeper-stage R&D rather than consumer products, but competes for talent, partnerships, and category mindshare.
• Unity Biotechnology: Clinical-stage biotechnology company developing senolytic therapeutics for age-related diseases, mentioned alongside Elysium in the longevity market landscape. Operates in the same senolytic space as Elysium's Senolytic Complex but pursues pharmaceutical rather than supplement pathways.

Others

• Lifespan.io (Life Extension Advocacy Foundation): Longevity research non-profit and consumer-facing media platform covering supplements, diagnostics, and interventions. Adjacent ecosystem player that shapes consumer perception and education in the longevity category in which Elysium competes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/elysiumhealth
• LinkedInlinkedin.com/company/elysium-health
• Instagraminstagram.com/elysiumhealth
• Xx.com/elysiumhq

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds7 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Elysium